-
in the AR-DMRI Department of Diabetes Immunology. The research is highly translational and primarily focused on human type 1 diabetes. The major ongoing projects are investigating miRNA biomarkers
-
, including first-in-human studies with genetically engineered hematopoietic stem and progenitor cells (HSPC) and T cells. As a successful candidate, you will: · Conduct research on next-generation
-
using transgenic and transplantation mouse models of lymphoproliferative diseases, primary cells from patients, humanized mice, gene editing, classical molecular, cell biology, and biochemistry, and
-
, experience in sequencing or protein structural data analysis is highly preferred. · Previous experience in working with animal models of human cancers · Literature knowledge of one of the three
-
, or immunotherapy. Previous experience in working with human specimens and development of novel, innovative cancer biomarkers. Evidence of scientific rigor and excellence as documented by high-impact peer-reviewed
-
intrafemoral transplantation assays, subcutaneous pump implantation for delivery of candidate therapies, utilizing humanized mouse models, conducting pre-clinical testing of immunotherapies in
-
cells in human body and the major components of primary tumors and the metastatic sites, macrophages are key effectors mediating tumor immunosurveillance and thus macrophage-based cancer immunotherapy is
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
include: working with mice, mammalian cell culture, primary human cell (BM and PBMC) culture and handling, multi-color FLOW cytometry, ELISA, and cell-sorting, co-culture functional assays. · Be
-
in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human